Navigation Links
Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Date:11/12/2007

ased awareness of the need for regular eye examinations by people with diabetics is important because of compliance issues among diabetics and the growing number of people with diabetes. Diabetic retinopathy affects an estimated 5.3 million people in the United States, as many as one-third of whom are unaware of their illness. People with diabetes are 25 times more likely to go blind than people who do not have the disease. Early detection and treatment of diabetic retinopathy significantly increases the chances of avoiding vision loss.

"There's been a tremendous push to raise diabetic retinopathy awareness and the need for regular eye examinations, but few other programs have demonstrated such a positive impact on overall rates of evaluation for diabetic retinopathy," said Dr. Zimmer-Galler.

Offering Quality Care to Premature Infants

In a second study presented at the annual meeting, researchers concluded that there was a high level of agreement between diagnoses of retinopathy of prematurity (ROP) made in low birth-weight babies using ophthalmoscopy and image-based telemedicine examinations.

"The number of premature infants is increasing throughout the world, and a larger percentage of them are surviving," said Michael Chiang, MD, assistant professor of ophthalmology and biomedical informatics at the Columbia University College of Physicians and Surgeons and presenting author of the paper. "The challenge is how do we make good care accessible to these babies. The purpose of this study was to see how well the results of telemedicine compared to those of an ophthalmoscopic examination."

Doctors at Columbia gathered data on 206 eyes from 67 prematurely born infants, performing up to two sets of examinations on each baby. In each instance, a pediatric ophthalmologist performed dilated indirect ophthalmoscopy on the infant to determine whether the baby had ROP. Diagnoses were classified in four categories: no ROP, mild ROP, type 2 prethres
'/>"/>

SOURCE American Academy of Ophthalmology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4Welcome to the Biofuel Age of Flight 12593 1Welcome to the Biofuel Age of Flight 12593 2Welcome to the Biofuel Age of Flight 12593 3Students May Be Solution to Shortage of Medical Professionals 48719 1Students May Be Solution to Shortage of Medical Professionals 48719 2Students May Be Solution to Shortage of Medical Professionals 48719 3Students May Be Solution to Shortage of Medical Professionals 48719 4Hey Governator 21 Dont Terminate Senior Funding 21 48717 1Hey Governator 21 Dont Terminate Senior Funding 21 48717 2Hey Governator 21 Dont Terminate Senior Funding 21 48717 3Hey Governator 21 Dont Terminate Senior Funding 21 48717 4Hey Governator 21 Dont Terminate Senior Funding 21 48717 5
Other Medicine Technology:Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 2Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 3Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 4Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 5Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 6Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 7Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 8BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7